Lechleiter: R&D breakthroughs on the horizon

01/28/2013 | Forbes

The push for personalized medicine, an emphasis on scientific advances and flourishing research into rare diseases suggest that the U.S. biopharmaceutical industry could be on the brink of a renaissance in drug research and development, writes Eli Lilly and Co. CEO John Lechleiter, who serves as chairman of PhRMA. An all-time high number of new drugs are in human testing, and more drugs are being developed for diseases without approved therapies in the past 10 years, Lechleiter writes.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD